Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued Sort descending
Ultomiris ravulizumab Neuromyelitis optica spectrum disorder (NMOSD) Active
Verzenio abemaciclib Adjuvant treatment of HR-positive, HER2-negative early breast cancer Active
Keytruda pembrolizumab Biliary tract carcinoma Active
Qulipta atogepant Migraine, prevention Active
Tagrisso osimertinib Non-small cell lung cancer Active
Vraylar cariprazine Schizophrenia Active
N/A Pembrolizumab Melanoma (Skin) Active
N/A Nivolumab and Ipilimumab Melanoma (Skin) Active
Tafinlar-Mekinist dabrafenib trametinib Advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation Pending
Erbitux Cetuximab Cancelled